MX2021011826A - Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas. - Google Patents
Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.Info
- Publication number
- MX2021011826A MX2021011826A MX2021011826A MX2021011826A MX2021011826A MX 2021011826 A MX2021011826 A MX 2021011826A MX 2021011826 A MX2021011826 A MX 2021011826A MX 2021011826 A MX2021011826 A MX 2021011826A MX 2021011826 A MX2021011826 A MX 2021011826A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- androgen receptor
- receptor inhibitors
- combinations including
- including androgen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825450P | 2019-03-28 | 2019-03-28 | |
| US201962842980P | 2019-05-03 | 2019-05-03 | |
| US201962857519P | 2019-06-05 | 2019-06-05 | |
| PCT/US2020/025539 WO2020198710A1 (en) | 2019-03-28 | 2020-03-27 | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011826A true MX2021011826A (es) | 2021-12-10 |
Family
ID=72610726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011826A MX2021011826A (es) | 2019-03-28 | 2020-03-27 | Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220202780A1 (enExample) |
| EP (1) | EP3947353A4 (enExample) |
| JP (1) | JP2022521824A (enExample) |
| KR (1) | KR20210144827A (enExample) |
| CN (1) | CN114502539A (enExample) |
| AU (1) | AU2020248105A1 (enExample) |
| CA (1) | CA3134545A1 (enExample) |
| IL (1) | IL286726A (enExample) |
| MX (1) | MX2021011826A (enExample) |
| WO (1) | WO2020198710A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| US12637418B2 (en) | 2019-01-24 | 2026-05-26 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as antagonist of NMDA |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| TWI873185B (zh) | 2019-09-16 | 2025-02-21 | 日商武田藥品工業股份有限公司 | 唑稠合之嗒-3(2h)-酮衍生物 |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| EP4135675A4 (en) * | 2020-04-17 | 2024-04-10 | Essa Pharma, Inc. | SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF |
| WO2022060969A1 (en) * | 2020-09-16 | 2022-03-24 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| WO2022169248A1 (ko) * | 2021-02-02 | 2022-08-11 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
| CA3215182A1 (en) * | 2021-04-16 | 2022-10-20 | Han-Jie Zhou | Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof |
| CN115340527B (zh) * | 2021-05-13 | 2023-09-15 | 成都先导药物开发股份有限公司 | 一种bcl-xl抑制剂及其制备方法和用途 |
| CN113603695B (zh) * | 2021-08-05 | 2022-06-14 | 青岛恒宁生物科技有限公司 | 一种取代的嘧啶胺类化合物或其作为农药可接受的盐、组合物及其用途 |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| AU2022340817A1 (en) * | 2021-09-01 | 2024-03-14 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| US20240398797A1 (en) * | 2021-09-01 | 2024-12-05 | Janssen Pharmaceutica Nv | Combination therapies for metastatic castration-resistant prostate cancer |
| WO2023151662A1 (zh) * | 2022-02-10 | 2023-08-17 | 上海奕拓医药科技有限责任公司 | 雄激素受体活性调节剂及其应用 |
| CN117065022A (zh) * | 2022-05-17 | 2023-11-17 | 海创药业股份有限公司 | 一种治疗三阴乳腺癌的药物 |
| WO2024006207A1 (en) * | 2022-06-26 | 2024-01-04 | Essa Pharma Inc. | An n-terminal domain androgen receptor inhibitor and uses thereof |
| EP4626878A1 (en) | 2022-12-02 | 2025-10-08 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| CN118255693A (zh) * | 2024-03-28 | 2024-06-28 | 大连理工大学 | 联苯类化合物及其在制备治疗白血病、肺癌以及乳腺癌药物中的应用 |
| CN121698845A (zh) * | 2024-09-12 | 2026-03-20 | 青岛普泰科生物医药科技有限公司 | 一种四氢喹啉类ntd抑制剂及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0709771B1 (pt) * | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| ES2613098T3 (es) * | 2011-08-19 | 2017-05-22 | British Columbia Cancer Agency Branch | Compuestos de éter de bisfenol fluorado y métodos para su uso |
| EP3733170A1 (en) * | 2012-07-13 | 2020-11-04 | Oncternal Therapeutics, Inc. | A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms) |
| FI3988541T3 (fi) * | 2015-01-13 | 2024-09-17 | British Columbia Cancer Agency Branch | Heterosyklisiä yhdisteitä syövän kuvantamiseksi ja hoitamiseksi ja menetelmiä niiden käyttämiseksi |
| US10980806B2 (en) * | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US20170298033A1 (en) * | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2017223115A1 (en) * | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
| AU2019362061B2 (en) * | 2018-10-18 | 2024-09-26 | Essa Pharma Inc | Androgen receptor modulators and methods for their use |
-
2020
- 2020-03-27 WO PCT/US2020/025539 patent/WO2020198710A1/en not_active Ceased
- 2020-03-27 MX MX2021011826A patent/MX2021011826A/es unknown
- 2020-03-27 US US17/599,338 patent/US20220202780A1/en not_active Abandoned
- 2020-03-27 AU AU2020248105A patent/AU2020248105A1/en not_active Abandoned
- 2020-03-27 EP EP20779267.2A patent/EP3947353A4/en not_active Withdrawn
- 2020-03-27 KR KR1020217034804A patent/KR20210144827A/ko not_active Ceased
- 2020-03-27 CN CN202080039623.3A patent/CN114502539A/zh active Pending
- 2020-03-27 CA CA3134545A patent/CA3134545A1/en active Pending
- 2020-03-27 JP JP2021557651A patent/JP2022521824A/ja not_active Ceased
-
2021
- 2021-09-26 IL IL286726A patent/IL286726A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022521824A (ja) | 2022-04-12 |
| EP3947353A1 (en) | 2022-02-09 |
| IL286726A (en) | 2021-12-01 |
| US20220202780A1 (en) | 2022-06-30 |
| NZ781283A (en) | 2024-09-27 |
| KR20210144827A (ko) | 2021-11-30 |
| EP3947353A4 (en) | 2023-07-05 |
| WO2020198710A1 (en) | 2020-10-01 |
| CA3134545A1 (en) | 2020-10-01 |
| AU2020248105A1 (en) | 2021-11-11 |
| CN114502539A (zh) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| ES3063344T3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
| DOP2015000189A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CO2017011536A2 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo | |
| ZA202308496B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX2016000510A (es) | Metodos para tratar cancer utilizando antagonistas de union al eje pd-1 e inhibidores de tigit. | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| MX2020001550A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| PE20150722A1 (es) | Moduladores de la expresion de receptores androgenicos que comprenden un oligonucleotido modificado | |
| CL2016003350A1 (es) | Inhibidores de demetilasa-1 especifica de lisina | |
| NI201900105A (es) | Terapia combinada para el cáncer de próstata | |
| CR20170085A (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2022006280A (es) | Uso de la composición para potenciar el efecto anticancerígeno que contiene el inhibidor de err? como principio activo. | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. | |
| MX2018003308A (es) | Suministro localizado de agente anti-fuctactico para tratamiento del cancer. | |
| CO6480929A2 (es) | Procedimiento de uso del factor liberador de corticotropina para el tratamiento del cancer |